11Jul 2022
Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infection

Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infection

This study studied viral culture dynamics post-treatment in a subset of participants receiving the mAb bamlanivimab in the ACTIV-2 trial. Viral load by qPCR and viral culture are performed from anterior nasal swabs collected on study days 0 (day of treatment), 1, 2, 3, and 7. Treatment with mAbs results in rapid clearance of the culturable virus. One day after treatment, 0 of 28 (0%) participants receiving mAbs and 16 of 39 (41%) receiving placebo still have culturable virus (p < 0.0001). Recrudescence of culturable virus is detected in three participants with emerging mAb resistance and viral RNA rebound.

  • #family health

Like

Save

Share